Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
Vertex Pharmaceuticals (VRTX) Receives a Hold from Scotiabank
In a report released today, Greg Harrison from Scotiabank maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...
Business Insider2d
Vertex Pharmaceuticals’ non-opioid painkiller approved by FDA, Bloomberg says
17:51 EST Vertex Pharmaceuticals (VRTX)’ non-opioid painkiller approved by FDA, Bloomberg says Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.
Reuters3d
US FDA approves Vertex's non-opioid painkiller
Jan 30 (Reuters) - The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' (VRTX.O), opens new tab drug to treat acute pain, the health regulator said on Thursday, offering a ...
Morningstar2d
Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug
Shares of Vertex Pharmaceuticals rose after Journavx, the company's oral non-opioid pain medication, received Food and Drug Administration approval. The Boston company's stock rose 4.3% ...
The Motley Fool6d
Is Vertex Pharmaceuticals Stock a Buy in 2025?
Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...
Business Wire2d
Vertex Announces FDA Approval of JOURNAVXâ„¢ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
As part of Vertex’s ongoing commitment to patients, the company has established patient support programs to help ensure that qualified patients can access JOURNAVX. For more information visit ...
Yahoo Finance6d
Is Vertex Pharmaceuticals Stock a Buy in 2025?
Vertex has built an empire in cystic fibrosis (CF) treatment, recently crowning its dominance with Alyftrek's approval last month. This latest CF drug adds even more firepower to a franchise ...